Transcription of Clinical Pharmacokinetic Studies of Pharmaceuticals
1 - 1 -- 2 -- 3 - - 4 - - 5 - - 6 -- 7 -- 8 -- 9 -- 10 - - 11 -- 12 -- 13 -- 14 -- 15 -- 16 - - 17 - - 18 -- 19 - - 20 - - 21 - - 22 - - 23.
Example: bankruptcy
Clinical Pharmacokinetic Studies of Pharmaceuticals
- 1 -- 2 -- 3 - - 4 - - 5 - - 6 -- 7 -- 8 -- 9 -- 10 - - 11 -- 12 -- 13 -- 14 -- 15 -- 16 - - 17 - - 18 -- 19 - - 20 - - 21 - - 22 - - 23.
- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され， 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Since 1874 遺伝子治療用製品の開発における 国内 …
www.nihs.go.jp遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名： n-(2-
毒物及び劇物取締法Q＆A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q＆A 質問一覧 1．毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Risk Assessment and Management of Genotoxic ... …
www.nihs.go.jpRisk Assessment and Management of Genotoxic Impurities in Pharmaceuticals Masamitsu Honma, Ph.D. Division of Genetics and …
Related documents
Guideline on the pharmacokinetic and clinical …
www.ema.europa.euGuideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) 4/38 69 Executive summary
Guideline on the pharmacokinetic and clinical …
www.ema.europa.euThe primary purpose of this guideline is to define the studies necessary to investigate the efficacy , safety, biopharmaceutic and pharmacokinetic properties of modified release formulations following
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comRegistration of Medicines Biosimilars . MEDICINES CONTROL COUNCIL. BIOSIMILAR MEDICINES QUALITY, NON-CLINICAL AND CLINICAL REQUIREMENTS